Sangamo Therapeutics
Sangamo Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Partnership
Sangamo is seeking new partners to continue advancing giroctocogene fitelparvovec, which reported positive Phase III results this year.
Sangamo Therapeutics to Seek FDA Accelerated Approval for Fabry Disease Gene Therapy
After meeting with the agency, the firm is optimistic it can submit a BLA for isaralgagene civaparvovec in the second half of 2025 using an intermediate endpoint.
Sangamo, Genentech Ink Deal to Advance Genomic Medicines for Alzheimer's, Other Neurological Diseases
Sangamo exclusively licensed certain technology to Genentech, which it will use to develop tau-directed medicines.
Pfizer to Discuss Positive Phase III Hemophilia A Gene Therapy Results With Regulators
Patients who received Pfizer and Sangamo Therapeutics' giroctocogene fitelparvovec experienced improvements in total annualized bleeding rate.
Sangamo Prices $24M Direct Offering of Common Stock
The firm will use the proceeds for general corporate purposes and to advance its pipeline of neurology-focused genomic medicines.
Sep 25, 2023